Detection of increasing mixed chimerism (IMC) using standard PCR correlates with relapse after allo-SCT for acute leukemias (ALs). Quantitative real-time PCR of insertion/deletion polymorphism (indel qrtPCR) is a much more sensitive method, which can be performed on peripheral blood. We studied the significance of low increases of recipient cells (0.1%) detected by indel qrtPCR in a cohort of 89 transplants. We did not observe relapse among the 32 patients with no IMC. Fifty-seven patients presented a first IMC, which was followed by four different scenarios: a decreasing MC (26 cases, no relapse), a stable MC (1 case, 1 relapse), a second IMC (24 cases, 15 relapse) or no control of chimerism (6 cases, 5 relapses). In multivariate analysis, detection of two successive IMCs was strongly associated with relapse (hazard ratio (HR): 9.4, 95% confidence interval (CI): 3.8-23; Po0.0001). Among the 57 patients who presented at least one IMC, 27 underwent immunomodulation (tapering of immunosuppression or donor lymphocyte injection), leading to a 1-year relapse rate of 15.7% vs 57.6% in the 30 other patients (P = 0.0007). Altogether, these results indicate that chimerism analysis using indel qrtPCR in peripheral blood is a useful tool for detection of relapse in patients transplanted for AL.
INTRODUCTION
Allo-SCT is an established method for treating high-risk acute leukemia (AL). Nevertheless, therapeutic success is mainly affected by relapse. [1] [2] [3] In that case, treatment options include administration of chemotherapy, withdrawal of immunosuppressive drugs, DLI or a second transplant, but outcome remains poor. Responses to DLI vary depending on the underlying hematologic malignancy, remission status at the time of DLI and use of disease-specific chemotherapy to reduce the tumor burden before DLI infusion. [4] [5] [6] [7] [8] [9] In AML, studies show that DLIs yield CR rates between 15 and 42%, with a 2-year OS of~20%. [10] [11] [12] [13] [14] These results can be improved by pre-DLI treatments as patients in CR before DLI shows a better survival. 14, 15 ALL responds poorly to DLI, but can possibly benefit patients who reached remission after salvage chemotherapy. 11, 16 These data suggest that post-transplant immunomodulation (IMod), consisting of withdrawal of immunosuppression or DLI, could be more effective in improving the outcome when performed before frank hematological relapse.
Monitoring of relapse after allo-SCT for AL is difficult because of the lack of reliable genetic markers of minimal residual disease (MRD) for all patients, in contrast with chimerism analysis, which is informative in almost all patients. Chimerism analysis allows the characterization of the hematopoietic stem cell origin in the recipient's blood or BM after allo-SCT. Several studies have used variable number tandem repeat or short tandem repeat (STR) PCR, and shown that the detection of increasing mixed chimerism (IMC) correlates with a greater risk of hematological relapse. [17] [18] [19] However, these techniques are not powerful enough to anticipate an impending cytological relapse because of their low sensitivity, that is, 1-5%, which is inferior to the detection of MRD using most genetic markers (Ig or T-cell receptor rearrangements, fusion transcripts, mutations or overexpression of genes). 20, 21 In addition, these techniques require BM samples to be sensitive enough and are therefore difficult to be performed on a routine basis. Quantitative PCR analysis using insertion/deletion polymorphism (indel qrtPCR) is a well-characterized and simple technique, which can be performed in peripheral blood with a better sensitivity compared with standard STR-PCR (0.01-0.1% vs 1-5%). 22, 23 While this technique has been previously used by others, [24] [25] [26] its usefulness to predict relapse at the recipient's cell level o1% has never been clearly evaluated.
The aim of the present study was to clarify the role of indel qrtPCR using low increases of recipient cells to define IMC in the detection and prediction of relapse after allo-SCT for AL.
MATERIALS AND METHODS

Study design
This monocentric retrospective study (Pitié-Salpêtrière Hospital, Paris, France) involved patients who were transplanted for AML or ALL between March 2004 and December 2009. To be included, donor-recipient pairs had to have an informative allele that could be chosen for indel qrtPCR analysis, and at least two chimerism analyses. The primary end point was to evaluate whether the detection of IMC was predictive of relapse.
Chimerism analysis
Chimerism analyses were performed at the Molecular Hematology Laboratory, at the Henri Mondor Hospital. Serial blood samples were collected at regular intervals after allo-HSCT. Genomic DNA extraction was performed from whole blood using either the QIAamp DNA mini-kit manual technique or the QIAsymphony DNA mini-kit automated technique, according to the manufacturer's recommendations (Qiagen, Courtaboeuf, France).
Chimerism analyses were performed using RQ-PCR of indel genomic polymorphisms on peripheral blood samples. Pretransplant host and donor genomic DNAs were amplified in parallel using a panel of 30 biallelic markers as previously described. 22 Quantification of the origin of posttransplant hematopoiesis was performed using the chosen host/donor informative-specific primers and probes. The percentage of host or donor hematopoietic genomic DNA was obtained by the ΔΔCt calculation method, where the post-HSCT hematopoietic DNA Ct is compared with the host or donor pre-HSCT DNA (100%) Ct, and the data are normalized with the Albumin reference gene Ct. When performed in triplicate the Ct s.d. allowed is 0.5 Ct. Knowing that a 1-Ct change corresponds to a 50% quantity variation, at low levels a 1-Ct decrease corresponds to an MC increase from 0.1 to 0.2% and a 3.2-Ct decrease corresponds to an mixed chimerism (MC) increase from 0.05 to 0.5% (1log increase).
Definitions
As the minimum detection level for this technique is 0.01%, 22, 23 we define complete chimerism (CC) as a recipient-cell percentage inferior to 0.01%, and MC as a recipient-cell percentage superior to this threshold. IMC was defined as an increase of the host cell percentage by at least 0.1% (that is, the detection of at least 0.1% recipient cells when previously strictly inferior to 0.1% or any increase of at least 0.1% above the 0.1% threshold). Patients were considered as having one IMC when the detection of IMC was not followed by another one and two IMCs when it was observed on two consecutive samples, without any decrease in between. In patients who presented several IMCs during their monitoring, only the first detected was analyzed.
Myeloablative conditioning regimen included at least 10 Gy fractionated TBI or high-dose BU (dose48 mg/kg orally or i.v. equivalent). Regimens not meeting these criteria were considered as reduced-intensity conditioning regimens. GVHD incidence was evaluated according to the international consensus recommendation (EBMT) and acute and chronic GVHD (aGVHD and cGVHD) were defined according to established criteria. 27 IM strategy was defined as the tapering of the immunosuppressive drugs (GVHD prophylaxis or treatment), occurring a maximum of 40 days after the detection of one IMC. Relapse was defined according to the Cheson-criteria: reappearance of leukemic blasts in the peripheral blood or 45% in the BM. 28 
Statistical analysis
The statistical analysis was based on the methodology of survival analysis. The main criteria were relapse and OS. For relapse analysis, death was considered as a censoring event. Occurrence of the various types of chimerism was considered as events for descriptive analysis, and as timedependent variables for risk-factor analysis for relapse and OS. aGVHD and cGVHD were also considered as time-dependent variables. For each criterion, descriptive statistics used survival function estimated by the Kaplan-Meier method and cumulative incidence function estimated as one minus the survival function. Univariate analyses were performed by log-rank tests for qualitative variables and univariate Cox models for quantitative and time-dependent variables. Multivariate analyses were based on the Cox model. The model parameters were estimated using stepwise regression, with variables with a P-value ⩽ 0.10 in the univariate analysis selected for the multivariate step, and variables with a P-value ⩽ 0.05 in the Wald test retained in the final models. All tests were two-sided, with a P-value ⩽ 0.05 considered as significant. Computations were performed using the SAS V9.3 statistical software (Brie Comte Robert, France).
RESULTS
Patients' characteristics
Ninety-one patients with AL received 95 allo-SCT during the period of the study. Six patients were excluded for lack of posttransplant chimerism analysis (early mortality in two and posttransplant evolutive disease in four patients). No patient was excluded for missing pre-transplant DNA or absence of informative chimerism allele. A total of 89 transplants in 85 patients (44 males and 41 females) were studied. Four patients received a second allogeneic transplant. Their characteristics and modalities of transplant are outlined in Table 1 . GVHD prophylaxis consisted of CYA and a short course of MTX for the myeloablative regimen, and in most cases, CYA alone for reduced-intensity conditioning. In the absence of GVHD, immunosuppressive drugs were mostly tapered after 4 months, but the timing varied depending on relapse risk and chimerism data. Three patients with a haploidentical transplant received a CD34 + cell-positive selection graft, without post-transplant immunosuppression.
Patients' outcome Twenty-one post-transplant relapses occurred, with a median time to transplant of 6 months (range 2-83). The 1-year and 3-year relapse incidence were 20.7% (95% confidence interval (CI), 11.9-29.5) and 28.9% (95% CI 17.6-40.1), respectively. Fifty patients developed aGVHD, 24 grade II-IV and 18 grade III-IV. The 2-year incidence of cGVHD was 27.8% (95% CI; 17.2-38.3). With a median follow-up of 30 months for the survivors (range 4-86), the 3-year OS was 57.4% (95% CI; 48.1-66.7). Thirty-six patients died after transplant: the causes of death were GVHD (n = 15), relapse (n = 14), infection (n = 2) and others (n = 5).
Chimerism analyses Analysis of chimerism was performed on 1007 peripheral blood samples, with a mean of 11 analyses per patient (range 2-26). According to our practice, on average the samples were collected once a month during the first 6 months, about every 2 months during the next 6-month period, every 3 months during the second year and about every 6 months thereafter.
During follow-up, MC with a recipient-DNA rate inferior to 1% and to 0.1% was observed in 86 and 77 transplants, respectively, and was reached with a median time of 40 days (range 9-200) and Indel qrtPCR chimerism in acute leukemia N Jacque et al 62 days (range 20-666), respectively. CC (o0.01% host markers) was achieved in 52 cases with a median time of 177 days (range 25-1287). The cumulative incidence of MCo 1%, MCo 0.1% and CC achievement is shown in Figure 1 . Chimerism evolution profiles were not significantly different between the types of conditioning regimen (myeloablative vs reduced intensity conditioning) ( Figure 2) . Thirty-two patients never presented an IMC during their monitoring. A first detection of IMC was observed in 57 cases, in a median time of 98 days after transplant (range 42-952). Among them, chimerism was not controlled in six cases, because of early death in one case (28 days after the first IMC, related to grade IV aGVHD) and because of rapid leukemia progression in three (at 7, 12 and 14 days after IMC). Among the 51 remaining patients, IMC was not confirmed by a second one in 27 cases (stable in 1 and decreasing in 26 cases). Finally, 24 patients had a second IMC at a median time of 126 days after transplant and 21 days after the first one (range 11-154).
Chimerism and relapse No relapse was observed in the 32 patients who did not present IMC and only one in the 27 patients with one isolated IMC (the only patient with stable MC) (Figure 3 ). In the group of six patients with a first IMC and no control, five patients relapsed, at a median time of 28.5 days after the IMC (interquartile range 12-49). Of the 24 patients with two IMCs, 15 relapsed, at a median time of 43 days after the first IMC (interquartile range 21-65). These 15 patients presented no clinical or hematological sign of relapse at the time of this analysis, except for 3 who presented mild cytopenia.
By univariate analysis, the 24 patients presenting two successive IMCs had significantly high risk of relapse in comparison with the 65 without IMC or with a single IMC (hazard ratio (HR): 8.09 (95% CI: 3.3-19.6); P o 0.0001). The level of chimerism reached (CC, MCo 0.1% or MCo1%) did not correlate with relapse (Table 2) . Relapse was also associated with disease status at transplant: the 3-year cumulative incidence of relapse for CR1, CR2 and no remission were 18.6%, 38.1% and 73.3%, respectively (P = 0.008). In multivariate analysis, these two variables remained strongly associated with the risk of relapse: two IMCs (HR: 9.4 (95% CI: 3.8-23); P o 0.0001)) and disease status at transplant (HR: 3.4 (95% CI: 1.4-8.3); P = 0.0053).
Chimerism and MRD
The correlation between MRD and chimerism was evaluated in 18 patients. MRD was assessed using the quantification of the following markers: BCR-ABL (n = 8), CBF-MYH11 (n = 2), PML-RARA (n = 1), MLL-AF6 (n = 1), MLL-AF9 (n = 1) and Wilms Tumor 1 (WT1) (n = 5). Among the 10 patients presenting an increasing MRD during follow-up (BCR-ABL (n = 4), WT1 (n = 5) and MLL-AF6 
Transplants n=89
One IMC n=57
No control of chimerism analysis n=6
Two successive IMC n=24
Stable MC n=1
Control of chimerism analysis n=51
Decrease MC n=26
No IMC n=32 Figure 3 . Scheme of chimerism results and patients' relapse according to chimerism profile. Abbreviations: CC = complete chimerism; CI = confidence interval; HR = hazard ratio; IMC = increasing mixed chimerism; MC = mixed chimerism; RIC = reduced intensity conditioning regimen.
Indel qrtPCR chimerism in acute leukemia N Jacque et al (n = 1)), 9 had a concomitant IMC and 5 of them relapsed with a median time of 39 days (range: 7-62) after the increasing MRD and 20 days (range: 7-59) after IMC. Five patients had an IMC (not confirmed by a second in four cases) without an increasing MRD, and did not relapse.
Post-IMC IMod
We studied the impact of post-transplant IMod in the 57 transplants with at least 1 IMC. Post-IMC IMod was observed in 27 cases (tapering of immunosuppressive drugs in ALL and DLI in 2 cases), within a median time of 8 days (interquartile range 0-28) after this IMC. Relapse occurred in only four of those patients. Six of them developed GVHD, leading to death in four (aGVHD grade IV after DLI in two and extensive cGVHD in the other two patients). In 30 cases (28 patients), IMC was not followed by IMod and 17 relapsed. In this population of 57 patients with one IMC, the cumulative incidence of relapse at 1 year was lower in patients with IMod compared with patients without IMod (15.7% (95% CI: 1.5-29.9%) vs 57.6% (95% CI: 39.5-75.7%); P = 0.0007) (Figure 4a) . In multivariate analysis, the two factors associated with the risk of relapse were IMod and disease status at transplant (HR: 0.19 (95% CI: 0.06-0.6), P = 0.0002 and HR: 1.74 (95% CI: 1.02-2.95), P = 0.035, respectively) ( Table 3 ). In the 24 patients with two successive IMCs, 10 underwent IMod. The cumulative incidence of relapse at 1 year in this group tends to be inferior to the 14 patients without IMod (76% vs 40%, P = 0.06) (Figure 4b ).
DISCUSSION
Chimerism analysis is commonly used to evaluate engraftment and predict relapse after allo-SCT. Fluorescence-based PCR amplification of STR is the gold standard for chimerism monitoring, recommended by the EuroChimerism Concerted Action. 29 Several studies based on this method have shown that detection of IMC strongly correlates with relapse after allo-SCT for AL. 17, 30, 31 However, owing to its poor sensitivity that does not allow the detection of o 1% of recipient cells, 10-25% of patients finally relapse despite achieving CC. In the opposite, quantitative analysis using indel polymorphism has a very high sensitivity close to 10 − 4 , but the previous studies using this method have not evaluated the usefulness of recipient-cell detection below the threshold of 1%. 25, 26, 32 In our study, we have defined IMC as small increases (at least 0.1%) of recipient cells, compatible with the sensitivity of indel qrtPCR, and evaluated whether such definition allows for a more accurate prediction of post-transplant relapse.
The first point that should be emphasized is the excellent negative predictive value of the technique, as no relapse occurred in patients exhibiting no IMC. Contrary to standard PCR, the risk of relapse is negligible as long as no IMC is detected in indel qrtPCR. As the patients of our series were not routinely monitored with standard PCR, we could not compare the two methods; however, if we had applied the definition commonly used with standard PCR (increased host cells above 1%), nine patients would present relapse with no IMC (data not shown). This result is consistent with the results from Koldehoff et al, 32 who showed that chimerism analysis with the qrtPCR method detects IMC better than the STR-PCR chimerism method does.
Importantly, we showed that the detection of two successive IMCs by indel qrtPCR using our definition was an excellent predictor of relapse, whereas the detection of only one IMC was not. Interestingly, among the 57 patients with at least one IMC, 23 had undergone IM, which could have prevented relapse by exerting a GVL effect. On the other hand, this might be due to the lack of specificity of monitoring MRD with chimerism analysis, as a recipient-specific marker and not a tumor-specific marker is used for monitoring. Indeed, recipient-cell reappearance does not necessarily indicate disease recurrence, but could indicate survival of normal-host hematopoiesis or a transient increase in recipient antiviral T lymphocyte. 33 In contrast, MRD monitoring using molecular genetics, tumor-specific molecular primers and mutiparameter flow cytometry are more specific tools for leukemiarelapse prediction. However, with the possible exception of CML, the specific techniques, timing, frequency and utility have not yet been clearly defined in the setting of allogeneic transplant. Furthermore, the lack of stability of some molecular markers or blast Ag expression from diagnosis and relapse raises concerns about the clinical usefulness of these techniques. 34 The second advantage of indel qrtPCR is that it can be performed on unfractionated peripheral blood samples, allowing frequent monitoring of chimerism. 22 By contrast, although standard PCR chimerism analysis is usually performed on peripheral blood, BM analysis is more informative for relapse prediction. 35 The frequency of chimerism analyses is important to establish because it will affect the predictive efficiency of the test (that is, frequently enough for early prediction of relapse, but not so frequent that waste of time and money ensues). Our data suggest that a monthly monitoring is sufficient to allow a prediction of relapse.
The impact of interventional strategies based on chimerism monitoring remains a matter of debate. In three prospective studies in AL pediatric cases, Bader et al. showed better EFS in patients who received IMod based on STR-PCR chimerism. [35] [36] [37] Zeiser et al. 38 evaluated the effect of IMod based on lineagespecific chimerism analysis by STR-PCR in myeloid malignancies, and all patients with IMC relapsed despite DLI or withdrawal of immunosuppressive drugs, probably because of the weak sensitivity of the technique and the definition of IMC, resulting in late detection of IMC. In our population, we found a lower relapse rate in patients who were offered IMod after IMC compared with those who were not. However, even if this result is interesting, the usefulness of IMod based on indel qrtPCR needs to be confirmed in a larger prospective study, where all patients will undergo IMod according to the same protocol.
In conclusion, chimerism analysis with indel qrtPCR is a sensitive and simple method to monitor the risk of relapse after allo-SCT for AL. This technique is able to detect mixed chimerism at a very low recipient-DNA threshold. We found an excellent negative predictive value as no relapse occurred in the absence of IMC. Patients with two successive IMC were at very high risk of relapse, and an IMod based on chimerism results appears to be effective to prevent relapse. Abbreviations: CI = confidence interval; HR = hazard ratio; IMC = increasing mixed chimerism; IMod = immunomodulation; MC = mixed chimerism; RIC = reduced intensity conditioning regimen.
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